MKI67 and breast cancer: This potential is exemplified by applications including AI-assisted mitosis counting [17], Gleason grading of prostate cancer [18, 19], breast cancer grading [20], counting Ki-67-positive cells [21], and the evaluation of therapeutic targets such as programmed cell death ligand 1 (PD-L1) [22].